DM
Therapeutic Areas
Novo Nordisk Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Wegovy HD (semaglutide 7.2mg) | Obesity | Approved |
| Glucose-sensitive insulin analogue | Type 1 & 2 Diabetes | Phase 1 |
| siRNA GalXC-GYS2 | Type 2 Diabetes | Phase 1 |
| Amylin analogue (subcutaneous) | Obesity | Phase 1 |
| CNP analogue | Heart Failure | Phase 1 |
| NLRP3 inhibitor | Cardiovascular Disease | Phase 1 |
| siRNA SLC25A5 | MASH | Phase 1 |
| Oral antibody fragment | Haemophilia | Phase 1 |
Leadership Team at Novo Nordisk
LF
Lars Fruergaard Jørgensen
President and CEO
KM
Karsten Munk Knudsen
EVP and CFO
MS
Marcus Schindler
EVP Research & Early Development, CSO
HW
Henrik Wulff
EVP Product Supply, Quality & IT
CS
Camilla Sylvest
EVP Commercial Strategy and Corporate Affairs
DL
Doug Langa
EVP North America
MD
Mike Doustdar
EVP International Operations
MH
Martin Holst Lange
EVP Development
LH
Ludovic Helfgott
EVP Rare Disease
TS
Thomas Senderovitz
SVP Data Science